Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dengue virus poses a major threat to global public health: two-thirds of the world's population is now at risk from infection by this mosquito-borne virus. Dengue virus causes a range of diseases with a small proportion of infected patients developing severe plasma leakage that leads to dengue shock syndrome, organ impairment and bleeding. Infection with one of the four viral serotypes results in the development of homotypic immunity to that serotype. However, subsequent infection with a different serotype is associated with an increased risk of developing severe disease, which has led to the suggestion that severe disease is triggered by immunopathology. This Review outlines recent advances in the understanding of immunopathology, vaccine development and human monoclonal antibodies produced against dengue virus.

Original publication

DOI

10.1038/nri3916

Type

Journal article

Journal

Nat Rev Immunol

Publication Date

12/2015

Volume

15

Pages

745 - 759

Keywords

Antibodies, Monoclonal, Dengue, Dengue Vaccines, Dengue Virus, Host-Pathogen Interactions, Humans, Life Cycle Stages, Models, Immunological, T-Lymphocytes